Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676421 | 1.00 | PDE5A (0.39) | PDE5ACD38P2RX3P2RX2EGFR | |
| SCHEMBL29676375 | 0.85 | CLK4 (0.43) | PDE5ACD38EGFRADORA2AKDM4E | |
| SCHEMBL22714770 | 0.85 | CLK4 (0.43) | PDE5ACD38EGFRADORA2AKDM4E | |
| SCHEMBL22714830 | 0.80 | PDE5A (0.40) | PDE5AKDM4EALDH1A1HTTCLK4 | |
| SCHEMBL28675697 | 0.79 | PDE5A (0.39) | PDE5AKDM4EALDH1A1HTTCLK4 | |
| SCHEMBL29676272 | 0.79 | PDE5A (0.39) | PDE5AKDM4EALDH1A1HTTCLK4 | |
| SCHEMBL22714679 | 0.79 | PDE5A (0.42) | PDE5AKDM4EALDH1A1HTTCLK4 | |
| SCHEMBL22714768 | 0.78 | P2RX3 (0.45) | PDE5AP2RX3P2RX2CLK4 | |
| SCHEMBL29481339 | 0.78 | P2RX3 (0.45) | PDE5AP2RX3P2RX2CLK4 | |
| SCHEMBL22714752 | 0.78 | PDE5A (0.36) | PDE5AP2RX3P2RX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | claimed |
| CN-113891745-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | claimed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-113891745-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020239952-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | claimed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | PDE5A 103/4885CD38 1022/4885P2RX3 1/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | PDE5A 103/4885CD38 1022/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.